Clinical Trials
27 trialsNCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT04372641 2025-09-17
Testing the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT05653661 2025-01-07
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
Phase 1 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT05600582 2023-10-18
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Codagenix, Inc
Phase 1 Withdrawn
NCT01632436 2023-10-02
Hepatic
CTI BioPharma
Phase 1 Withdrawn
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT05472220 2022-12-27
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
University of California, San Francisco
Phase 1 Withdrawn
NCT05010096 2022-05-27
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01461252 2021-07-16
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Boston Scientific Corporation
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT02300935 2019-05-30
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT02581501 2019-04-18
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Stamford Hospital
Phase 1 Withdrawn
NCT00005030 2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02839694 2018-07-05
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02105350 2018-02-19
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
University Health Network, Toronto
Phase 1 Withdrawn
NCT02210104 2017-07-21
Adoptive Therapy Using Antigen-Specific CD4 T-Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01685489 2015-10-27
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
Phase 1 Withdrawn
NCT00247403 2015-04-10
Safety Study of 2DG With Stereotactic Radiosurgery
University of Iowa
Phase 1 Withdrawn
NCT02205463 2014-08-01
KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
NYU Langone Health
Phase 1 Withdrawn
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn
NCT01333423 2012-06-26
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1 Withdrawn